Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    Added a new revision entry (Revision: v3.3.3) to the Record History and removed the previous Revision: v3.3.2 along with the HHS Vulnerability Disclosure link.
    Difference
    0.2%
    Check dated 2025-12-23T20:34:34.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    No Change Detected
  5. Check
    37 days ago
    Change Detected
    Summary
    The page footer now displays Revision: v3.3.2, replacing the previous Revision: v3.2.0.
    Difference
    0.1%
    Check dated 2025-11-25T10:28:50.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The deletion removes the government funding/operating status notice that previously warned about updates and where to check for current information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.6%
    Check dated 2025-11-18T06:52:13.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The new screenshot shows cosmetic UI adjustments such as header spacing and minor layout tweaks; substantive study content and version history appear unchanged.
    Difference
    0.1%
    Check dated 2025-11-03T20:54:15.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    - Updated the page to include a government-operating-status notice and a new version tag (v3.2.0), replacing the old v3.1.0.
    Difference
    11%
    Check dated 2025-10-06T05:17:47.000Z thumbnail image
  9. Check
    95 days ago
    Change Detected
    Summary
    Changed the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.
    Difference
    0.3%
    Check dated 2025-09-29T02:58:56.000Z thumbnail image

Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.